ArticleCancer medicine2018

Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting.

Sarah S Mougalian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.